Press Releases

Press Releases
Date Title and Summary View
Jun 6, 2010 BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from a National Cancer Institute-sponsored clinical study were presented by representatives of a network of researchers led by the Cancer and Leukemia Group B (CALGB) at the annual meeting of the ...
Jun 6, 2010 BOUDRY, Switzerland, Jun 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) today announced that data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the American Society of Clinical Oncology. Results of the stu...
Jun 7, 2010 BOUDRY, Switzerland, Jun 07, 2010 (BUSINESS WIRE) --ABSTRACT #6508 Celgene International Sàrl (NASDAQ:CELG) today announced thatresearchers presented data from an investigator-initiated Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the ann...
Jun 12, 2010 BOUDRY, Switzerland, Jun 12, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomized, double-blind study of continuous REVLIMID (lenalidomide) for the treatment of elderly patients with new...
Jun 14, 2010 SUMMIT, N.J., Jun 14, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overvi...
Jun 24, 2010 (June 24, 2010) – Celgene International Sàrl (NASDAQ: CELG) announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients with relapsed or refract...
Jun 30, 2010 SUMMIT, N.J. & LOS ANGELES, Jun 30, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG)and Abraxis BioScience Inc. (Nasdaq: ABII) today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merg...
Jul 19, 2010 SUMMIT, N.J., Jul 19, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, July 29, 2010 at 9 a.m. ET to discuss the company's second quarter 2010 financial and operational results. The webcast will be available in the inv...
Jul 29, 2010 SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAA...
Aug 4, 2010 SUMMIT, N.J., Aug 04, 2010 (BUSINESS WIRE) --Celgene Corporation (NASDAQ: CELG) today announced that it has received verbal confirmation of early termination of the Hart-Scott-Rodino Act (HSR) 30-day waiting period without the United States Federal Trade Commission (FTC) requesting additional information with regar...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase